Last updated: September 13, 2026
AFSTYLA is CSL Behring's recombinant, single-chain factor VIII replacement therapy for hemophilia A. Its commercial position is supported by a differentiated molecular design, established CSL Behring distribution, and demand for extended-interval factor replacement. Its main constraints are competition from longer-acting factor VIII products, subcutaneous emicizumab, gene therapy, and the absence of separately disclosed product revenue in CSL's public financial reporting.
FDA approval was granted on May 20, 2016. The biologic reference-product exclusivity period is expected to run through May 20, 2028, subject to the statutory operation of the Biologics Price Competition and Innovation Act. AFSTYLA is not listed in the FDA Orange Book because biologic products are tracked through the Purple Book rather than the Orange Book. [1][2]
What is AFSTYLA and how does its technology differ from competing factor VIII drugs?
AFSTYLA is lonoctocog alfa, a recombinant factor VIII product manufactured by CSL Behring. It uses a single-chain factor VIII molecule designed to improve stability and maintain interaction between the heavy and light chains of factor VIII.
The product is approved for:
- On-demand treatment and control of bleeding episodes
- Perioperative management of bleeding
- Routine prophylaxis to reduce bleeding frequency
- Use in adults and children with hemophilia A
AFSTYLA does not contain von Willebrand factor and is produced without human plasma-derived components. The FDA label reports a terminal half-life approximately 1.5 times that of conventional full-length factor VIII products in the evaluated patient population. [1]
AFSTYLA dosing and delivery profile
Routine prophylaxis generally uses 20 to 50 international units per kilogram two to three times weekly, with dosing individualized according to the patient's response, bleeding pattern, and factor VIII recovery. AFSTYLA is administered intravenously.
Its clinical value proposition is based on:
- Single-chain molecular stability
- Lower infusion frequency than some standard half-life factor VIII regimens
- Established factor VIII efficacy without the immunogenicity and delivery changes associated with gene therapy or subcutaneous products
The product remains dependent on intravenous administration. That limits convenience relative to Hemlibra, which is administered subcutaneously, and gene therapies that may provide longer-term endogenous factor VIII expression in selected patients.
How does AFSTYLA compare with Eloctate, Advate, Jivi, Esperoct, and Altuviiio?
AFSTYLA competes in a segmented factor VIII market rather than a single uniform category.
| Product |
Active ingredient or modality |
Manufacturer |
Administration |
Commercial positioning |
| AFSTYLA |
Lonoctocog alfa, single-chain recombinant factor VIII |
CSL Behring |
Intravenous |
Extended half-life, single-chain factor VIII |
| Advate |
Octocog alfa, recombinant factor VIII |
Takeda |
Intravenous |
Established standard-half-life factor VIII |
| Eloctate |
Eftrenonacog alfa, Fc-fusion factor VIII |
Sanofi |
Intravenous |
Extended half-life factor VIII |
| Jivi |
Damoctocog alfa pegol |
Bayer |
Intravenous |
PEGylated extended-half-life factor VIII |
| Esperoct |
Turoctocog alfa pegol |
Novo Nordisk |
Intravenous |
PEGylated extended-half-life factor VIII |
| Altuviiio |
Efanesoctocog alfa |
Sanofi |
Intravenous |
Very extended half-life factor VIII |
| Hemlibra |
Emicizumab-kxwh, bispecific antibody |
Roche/Genentech |
Subcutaneous |
Non-factor prophylaxis |
| Roctavian |
Valoctocogene roxaparvovec |
BioMarin |
One-time intravenous gene therapy |
Gene therapy for selected adults |
Altuviiio has the strongest recent competitive effect within the factor VIII replacement segment because its approved prophylaxis schedule can be weekly or less frequent depending on the regimen and clinical circumstances. Hemlibra has a broader commercial effect because it changes the delivery model from intravenous factor replacement to subcutaneous prophylaxis. [3][4][5]
AFSTYLA's most defensible commercial niches are patients who:
- Prefer or require factor VIII replacement
- Have established treatment routines with CSL Behring
- Value extended half-life without switching to a non-factor product
- Need perioperative or acute bleeding treatment based on measured factor VIII replacement
- Are unsuitable for, or unwilling to pursue, gene therapy
What is the financial trajectory of AFSTYLA?
CSL does not consistently report AFSTYLA revenue as a separate audited line item in its consolidated financial statements. The product is reported within CSL Behring's broader revenue and therapeutic-area disclosures. This prevents a reliable public calculation of AFSTYLA-specific revenue, operating margin, or geographic revenue by year. [6]
The available financial picture supports a mature-growth interpretation:
| Financial factor |
Effect on AFSTYLA |
| CSL Behring commercial platform |
Supports global access, contracting, and specialist distribution |
| Hemophilia A prevalence |
Provides a recurring treatment population |
| Extended-half-life positioning |
Supports premium pricing relative to standard-half-life factor VIII |
| Competitive launches |
Limits volume growth and increases rebate pressure |
| Hemlibra adoption |
Reduces demand for routine intravenous factor prophylaxis |
| Altuviiio adoption |
Increases pressure on extended-half-life factor VIII products |
| Manufacturing scale |
Supports supply reliability but requires high-cost biologic production |
| Product-level disclosure |
Limits external assessment of standalone revenue and profitability |
CSL Behring's broader revenue growth has been driven primarily by immunoglobulins and other plasma-derived products rather than AFSTYLA alone. AFSTYLA should therefore be evaluated as a strategic specialty product within CSL Behring's hemophilia portfolio, not as a separately reported public-company growth engine.
Revenue exposure and commercial sensitivity
AFSTYLA revenue is exposed to four measurable commercial variables:
- Patient switching between factor VIII products
- Adoption of non-factor prophylaxis
- Payer treatment protocols and rebate competition
- The number of patients remaining on intravenous factor replacement after gene therapy expansion
The highest near-term revenue risk is substitution within prophylaxis. Patients who require factor VIII for surgery or breakthrough bleeding may remain commercially relevant even if routine prophylaxis shifts toward Hemlibra or gene therapy. That creates a potential split between declining prophylaxis volume and continuing episodic or perioperative demand.
When does AFSTYLA lose FDA biologic exclusivity?
AFSTYLA was approved by the FDA on May 20, 2016. Under the BPCIA, a licensed biological reference product receives 12 years of reference-product exclusivity. On that basis, the statutory exclusivity period is expected to expire on May 20, 2028. [1][2]
| Milestone |
Date or status |
| FDA approval |
May 20, 2016 |
| Reference-product exclusivity |
Expected through May 20, 2028 |
| Earliest likely biosimilar approval date based solely on 12-year exclusivity |
May 20, 2028 |
| Earliest commercial launch |
Depends on patent litigation, settlements, injunctions, and licensing |
| Orange Book listing |
Not applicable |
| Purple Book reference product |
Applicable |
Loss of reference-product exclusivity does not automatically permit commercial biosimilar entry. A biosimilar sponsor must complete the FDA 351(k) pathway, address applicable patents, and manage any litigation or settlement restrictions. A biosimilar could be approved after the exclusivity period but remain subject to a later patent-based launch date.
What patents protect AFSTYLA?
AFSTYLA's protection is likely to involve several patent categories rather than a single composition-of-matter right:
- Recombinant factor VIII molecule and single-chain architecture
- Amino-acid sequence modifications
- Expression constructs and host-cell production
- Cell culture and purification processes
- Formulation and stability
- Pharmaceutical compositions
- Methods of treating hemophilia A
- Dosing and prophylaxis regimens
The commercial product is a recombinant biologic, so patent analysis requires review of U.S. and foreign patent families, continuations, terminal disclaimers, patent-term adjustments, and claim scope. Product-specific patent information is not consolidated in the Orange Book.
Publicly available FDA materials confirm the approved product and label but do not provide a complete, authoritative AFSTYLA patent table. A definitive freedom-to-operate conclusion cannot be drawn from FDA labeling alone. [1]
Are AFSTYLA formulation patents commercially important?
Formulation and manufacturing patents can remain relevant after a core molecule patent expires. They may cover:
- Stabilized lyophilized or liquid presentations
- Buffer systems
- Excipient combinations
- Protein concentration and storage conditions
- Recombinant expression and purification steps
Their practical value depends on claim breadth and whether a biosimilar can use a non-infringing formulation or manufacturing process. Manufacturing claims are often more difficult for a biosimilar sponsor to assess because process details may be confidential and unavailable before litigation.
Are there Paragraph IV challenges to AFSTYLA?
Paragraph IV certification applies to patents listed in the Orange Book for small-molecule products. AFSTYLA is a biologic and is not governed by the Orange Book Paragraph IV framework.
A competing biologic would generally use the 351(k) biosimilar pathway. Patent disputes would proceed under the BPCIA's patent-information exchange and litigation framework, often called the "patent dance," or through other declaratory-judgment and infringement actions. [2]
No publicly established AFSTYLA biosimilar litigation or settlement should be assumed without a current review of FDA, federal court, and company filings. The absence of a publicly identified dispute does not eliminate future patent risk.
What is the FDA and Orange Book status of AFSTYLA?
AFSTYLA is FDA-approved and regulated as a biologic under section 351(a) of the Public Health Service Act. It is not an Orange Book-listed drug.
| Regulatory issue |
AFSTYLA status |
| FDA product type |
Biologic |
| Approval pathway |
Section 351(a) BLA |
| BLA holder |
CSL Behring LLC |
| Active ingredient |
Lonoctocog alfa |
| Therapeutic area |
Hemophilia A |
| Orange Book listing |
No |
| Purple Book relevance |
Yes |
| Biosimilar pathway |
Section 351(k) |
| Pediatric use |
Approved in children and adults |
| Administration |
Intravenous |
The FDA label includes a boxed warning for hypersensitivity reactions and a warning concerning development of neutralizing antibodies, or inhibitors, to factor VIII. [1]
What patent litigation and settlement risks affect AFSTYLA?
The principal future litigation risk is a biosimilar challenge to patents covering the product, manufacturing process, formulation, or use. The timing would depend on:
- The date of a 351(k) filing
- Exchange of patent information
- Selection of patents for litigation
- Preliminary or permanent injunction requests
- Patent-term adjustments and extensions
- Any license or settlement agreement
- The biosimilar sponsor's willingness to launch at risk
No public settlement date or licensed biosimilar launch date establishes an AFSTYLA generic-entry schedule. "Generic entry" is technically inaccurate for this product; the relevant term is biosimilar entry.
How strong is the AFSTYLA patent estate?
AFSTYLA's patent estate is commercially meaningful but difficult to rate as high strength or low strength without claim charts against specific biosimilar molecules and manufacturing processes.
Strengths
- Complex biologic manufacturing creates process barriers
- Single-chain factor VIII technology can generate composition and method claims
- Manufacturing know-how may supplement formal patent protection
- CSL Behring has an established global regulatory and commercial platform
- Biosimilar development requires analytical comparability and clinical justification
Weaknesses
- The original 2016 approval date places the product near the end of its 12-year U.S. reference-product exclusivity period
- Competing factor VIII products are already established
- A biosimilar may avoid selected formulation or process claims
- Hemlibra and gene therapy compete without needing to copy AFSTYLA
- Product-specific revenue is not separately disclosed, reducing visibility into commercial resilience
The estate is likely stronger as a combined regulatory, manufacturing, know-how, and patent package than as a single long-duration molecule monopoly.
What generic and biosimilar launch scenarios exist for AFSTYLA?
Scenario 1: No near-term biosimilar launch
A biosimilar sponsor may delay development because the market is fragmented and competing products already include Hemlibra and Altuviiio. The cost of developing a factor VIII biosimilar may not justify rapid entry if expected price erosion is high.
Scenario 2: Launch after reference-product exclusivity
A 351(k) sponsor could seek approval after May 20, 2028, then launch after resolving patent disputes. This would create the clearest direct price pressure on AFSTYLA.
Scenario 3: Settlement-based delayed entry
CSL Behring and a biosimilar sponsor could settle litigation with an agreed entry date. The date could precede the expiry of some patents while remaining later than the statutory exclusivity date, depending on the settlement terms and applicable law.
Scenario 4: Limited commercial impact
A biosimilar could enter but gain limited share because physicians and patients may prioritize established supply, inhibitor monitoring, specialty pharmacy support, or clinical familiarity. The greater risk may come from non-biosimilar alternatives such as Hemlibra and Altuviiio.
How does AFSTYLA compare with Hemlibra and Altuviiio commercially?
AFSTYLA competes with Hemlibra on convenience and with Altuviiio on factor VIII duration.
| Dimension |
AFSTYLA |
Hemlibra |
Altuviiio |
| Treatment class |
Factor VIII replacement |
Non-factor bispecific antibody |
Extended-half-life factor VIII |
| Route |
Intravenous |
Subcutaneous |
Intravenous |
| Primary advantage |
Factor replacement with extended half-life |
Less frequent, non-intravenous prophylaxis |
Very extended factor VIII exposure |
| Main limitation |
IV administration |
Does not replace factor VIII directly |
Premium pricing and IV administration |
| Surgical/acute bleeding role |
Direct factor replacement |
Requires additional hemostatic planning |
Direct factor replacement |
| Biosimilar exposure |
Possible after BPCIA pathway |
Biologic competition, but different modality |
Possible after BPCIA pathway |
AFSTYLA retains clinical relevance where direct factor replacement is preferred or required. Its competitive risk is highest in routine prophylaxis, where convenience and administration frequency can outweigh molecular differentiation.
What geographic markets matter for AFSTYLA?
The United States is strategically important because of high treatment spending, specialty pharmacy infrastructure, and the potential impact of U.S. biosimilar entry. Europe is also important, but reimbursement systems and centralized health-technology assessment create stronger price and tender pressure.
Key geographic variables include:
- National reimbursement of extended-half-life factor VIII
- Hospital and tender purchasing
- Hemophilia treatment-center protocols
- Availability of competing extended-half-life products
- Gene-therapy reimbursement
- Local patent terms and supplementary protection rights
- CSL Behring's manufacturing and distribution footprint
Patent expiry and biosimilar entry will not occur on a single global date. U.S., European, and other national rights must be analyzed separately.
Key Takeaways
- AFSTYLA is CSL Behring's single-chain recombinant factor VIII for hemophilia A.
- FDA approval occurred on May 20, 2016.
- The expected 12-year U.S. biologic reference-product exclusivity period runs through May 20, 2028.
- AFSTYLA is not Orange Book-listed; biosimilar disputes proceed under the BPCIA and 351(k) framework.
- CSL does not provide consistently separate audited AFSTYLA revenue, so product-specific financial growth cannot be verified from consolidated public accounts.
- Commercial pressure comes from Hemlibra, Altuviiio, other extended-half-life factor VIII products, and gene therapy.
- The patent estate likely includes molecule, formulation, manufacturing, and method-of-use protection, but its effective strength depends on claim scope and biosimilar process design.
- No public AFSTYLA Paragraph IV challenge should be expected because Paragraph IV applies to Orange Book-listed small-molecule drugs.
- The main launch risk after 2028 is biosimilar entry combined with existing non-biosimilar substitution.
- AFSTYLA's long-term value depends more on retention within the factor VIII segment than on broad market expansion.
Frequently Asked Questions
Is AFSTYLA a biologic or a generic drug?
AFSTYLA is a biologic. A competing product would generally be developed as a biosimilar under section 351(k), not as an ANDA generic.
Does AFSTYLA have an Orange Book patent listing?
No. FDA-approved biologics such as AFSTYLA are tracked through the Purple Book rather than the Orange Book.
What is the active ingredient in AFSTYLA?
The active ingredient is lonoctocog alfa, a recombinant single-chain factor VIII.
Can AFSTYLA be replaced by Hemlibra?
Hemlibra can replace factor-based routine prophylaxis for many patients, but it is not a factor VIII product. Treatment decisions depend on bleeding history, inhibitor status, surgery, breakthrough bleeding, and physician management.
What is the main commercial threat to AFSTYLA after 2028?
The main threat is combined substitution from biosimilar factor VIII, longer-acting factor VIII products such as Altuviiio, subcutaneous Hemlibra, and gene therapy. The relative impact will depend on reimbursement, clinical practice, and patient switching.
References
- U.S. Food and Drug Administration. (2016). AFSTYLA (lonoctocog alfa) prescribing information.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
- U.S. Food and Drug Administration. (2023). ALTUVIIIO (efanesoctocog alfa) prescribing information.
- U.S. Food and Drug Administration. (2018). HEMLIBRA (emicizumab-kxwh) prescribing information.
- U.S. Food and Drug Administration. (2024). ROCTAVIAN (valoctocogene roxaparvovec-rvox) prescribing information.
- CSL Limited. (2024). Annual report 2024.
